预约演示

更新于：2025-02-22

Amphotericin B

两性霉素B

更新于：2025-02-22

概要

基本信息

药物类型

小分子化药

别名

SinuNase、CM001、DKF-5122

+ [16]

靶点

Ergosterol

作用机制

Ergosterol 调节剂(麦角固醇调节剂)

治疗领域

感染神经系统疾病心血管疾病+ [4]

在研适应症

利什曼病粒细胞减少性发热念珠菌病+ [8]

非在研适应症

急性髓性白血病慢性皮肤黏膜念珠菌病侵袭性念珠菌病+ [7]

原研机构

Vestar Development Co.

在研机构

Sumitomo Pharma Co., Ltd.

Matinas Biopharma Nanotechnologies, Inc.

Matinas BioPharma Holdings, Inc.

+ [5]

非在研机构

Enzon Pharmaceuticals, Inc.

石药集团中奇制药技术（天津）有限公司

DongKook Pharmaceutical Co., Ltd.

最高研发阶段批准上市

首次获批日期

(1958-01-01),

真菌病

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、合格传染病产品 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C47H73NO17

InChIKeyAPKFDSVGJQXUKY-INPOYWNPSA-N

CAS号1397-89-3

关联

115

项与两性霉素B 相关的临床试验

NCT06525389

/ Not yet recruiting临床3期IIT

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions:
1. Is induction therapy using a single 10 mg/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?

开始日期2025-01-06

申办/合作机构

Duke University

[+6]

ChiCTR2400094386

/ Suspended临床4期IIT

Clinical study of amphotericin B nebulized inhalation in the prevention of invasive fungal infections of the lungs in artificial liver therapy

开始日期2025-01-01

申办/合作机构-

NCT06447402

/ Recruiting临床3期IIT

A Randomized Controlled Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Increasing Time to Relapse in Patients With Chronic Pulmonary Aspergillosis Treated With 12 Months of Oral Itraconazole

The treatment of CPA is with oral itraconazole for 6-12 months. Oral itraconazole results in better clinical outcomes in CPA compared to supportive care. A recent study comparing 6 months with 12 months of oral itraconazole for longer duration treatment found longer duration reduced CPA relapse and improved clinical outcomes. However, longer duration of itraconazole could cause emergence of drug resistant Aspergillus fumigatus and therapy related adverse event. A recent study found nebulized amphotericin B non-inferior to oral itraconazole for treating CPA as primary therapy. However, the study was small and included patients with simple aspergilloma and used nebulized amphotericin B for 7 days.To be effective, an inhaled drug should be delivered in sufficient quantity to achieve therapeutic levels.The minimum inhibitory concentration of amphotericin B for A.fumigatus is 0.5 mg/L. In one study, nebulization of 30 mg of amphotericin B deoxycholate achieved a mean concentration of 0.68 mg/L in the bronchoalveolar lavage fluid. Notably, the serum levels of amphotericin B after nebulization are 20 times less than after systemic administration and is safer. Further, there is a dose-response relation with nebulized amphotericin B, the higher the dose used for nebulization, the higher are the levels achieved in the lung tissue. Nebulized amphotericin B has been used in lung transplant recipients to prevent invasive aspergillosis. Also, two recent studies have demonstrated that use of nebulized amphotericin B as maintenance therapy led to a reduction in ABPA relapse rates and prolonged time to exacerbation. We believe that inhaled amphotericin B as a maintenance therapy could reduce CPA relapse and prolong time to relapse. In this study, we plan to evaluate nebulized amphotericin B as a maintenance therapy in clinically stable CPA patients treated with 12 months of oral antifungal therapy

开始日期2024-06-03

申办/合作机构

Post Graduate Institute of Medical Education & Research

100 项与两性霉素B 相关的临床结果

登录后查看更多信息

100 项与两性霉素B 相关的转化医学

登录后查看更多信息

100 项与两性霉素B 相关的专利（医药）

登录后查看更多信息

28,235

项与两性霉素B 相关的文献（医药）

2025-12-01·JOURNAL OF CLINICAL IMMUNOLOGY

Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity

Review

作者: Xing, Shubin ; Zhao, Xiaodong ; Tang, Xuemei ; Zhang, Zhenzhen ; An, Yunfei ; Liu, Cong ; He, Wuyang ; Chen, Yongwen ; Zhang, Wenjing ; Zhang, Zhiyong

BACKGROUND:

Talaromyces marneffei (T. marneffei) is an opportunistic pathogen that causes endemic mycoses, which could lead to multiple organ damage. Talaromycosis is frequently disregarded as an early cautionary sign of immune system disorders in non-HIV-infected children.

OBJECTIVE:

We conduct a comprehensive review of the genotypes and clinical features of talaromycosis in patients with IEI to enhance clinical awareness regarding T. marneffei as a potential opportunistic pathogen in individuals with immune deficiencies.

METHODS:

A systematic literature review was performed by searching PubMed, Cochrane Central Register of Controlled Trials, Web of Science, EMBASE, and Scopus. Data on IEI patients with talaromycosis, including genotypes and their immunological and clinical features, were collected.

RESULTS:

Fifty patients with talaromycosis and IEI were included: XHIM (30.0%), STAT3-LOF deficiency (20.0%), STAT1-GOF (20.0%), IL2RG (6.00%), IFNGR1 (6.0%), IL12RB1 (4.0%), CARD9 (4.0%), COPA (4.0%), ADA (2.0%), RELB deficiency (2.0%), and NFKB2 (2.0%). Common symptoms of respiratory (43/50, 86.0%), skin (17/50, 34.0%), lymph node (31/50, 62.0%), digestive (34/50, 68.0%), and hematologic (22/50, 44.0%) systems were involved. The CT findings of the lungs may include lymph node calcification (9/30), interstitial lesions (8/30), pulmonary cavities (8/30), or specific pathogens (4/30), which could be easily misdiagnosed as tuberculosis infection. Amphotericin B (26/43), Voriconazole (24/43) and Itraconazole (22/43) were used for induction therapy. Ten patients were treated with Itraconazole sequentially and prophylaxis. 68.0% (34/50) of patients were still alive, and 4.0% (2/50) of were lost to follow-up. The disseminated T. marneffei infection resulted in the deaths of 14 individuals.

CONCLUSIONS:

The XHIM, STAT1-GOF, and STAT3-LOF demonstrated the highest susceptibility to talaromycosis, indicating the potential involvement of cellular immunity, IL-17 signaling, and the IL-12/IFN-γ axis in T. marneffei defense. T. marneffei infection may serve as an early warning indicator of IEI. For IEI patients suspected of T. marneffei, metagenomic next-generation sequencing (mNGS) could rapidly and effectively identify the causative pathogen. Prompt initiation of antifungal therapy is crucial for optimizing patient outcomes.

2025-12-01·JOURNAL OF CLINICAL IMMUNOLOGY

Disseminated Aspergillosis in X-linked Agammaglobulinemia: Beyond the norm

Article

作者: Rawat, Amit ; Vignesh, Pandiarajan ; Jindal, Ankur Kumar ; Thangaraj, Abarna ; Goel, Sumit ; Sil, Archan

X-linked agammaglobulinemia (XLA) due to a mutation in Bruton's tyrosine kinase (BTK), leads to the arrested development of B cells at the pro-B cell stage. This results in absent B cells and severe hypogammaglobulinemia. XLA patients usually present with recurrent sinopulmonary infection. Bacterial infections are the commonest [2], fungal infections like Pneumocystis jirovecii, Aspergillus and Candida species are rarely reported and they are associated with mortality in XLA [3]. We report a 3.5-year-old boy with disseminated aspergillosis, an uncommon presentation of XLA. Despite treatment with antifungals, including voriconazole and amphotericin B, the patient succumbed to the illness. Genetic analysis revealed a pathogenic variant in the BTK gene (R28H), confirming XLA diagnosis. This case highlights the potential for severe fungal infections in XLA patients and suggests broader immune system dysregulation beyond B-cell defects.

2025-06-01·Journal of Stomatology Oral and Maxillofacial Surgery

Delayed maxillary reconstruction following mucormycosis: A comprehensive analysis of surgical strategies and outcomes

Article

作者: Garg, Paheli ; Goil, Pradeep ; Charan Pahari, Dr Kaushal ; Charan Pahari, Kaushal ; Goil, Dr Pradeep ; Vashistha, Aakansha ; Vashistha, Dr Aakansha ; Garg, Dr Paheli

STUDY DESIGN:

This study is a prospective observational study conducted over two years from December 2020 to March 2023 at the Department of Plastic and Reconstructive Surgery.

OBJECTIVE:

To evaluate the outcomes of delayed reconstruction in patients with maxillectomy defects post-COVID-19 associated mucormycosis, focusing on safety, morbidity, and aesthetic results.

METHODS:

Fifty patients with post-COVID-19 mucormycosis and maxillectomy defects without skin involvement were included. These patients underwent radical debridement and were treated with Amphotericin B followed by Posaconazole therapy until clinical and radiological resolution of the disease. Reconstruction was performed after a minimum of six months post-maxillectomy. Flaps used for reconstruction included the radial forearm free flap (RAFF), anterolateral thigh flap (ALT), and free fibula osteomyocutaneous flap, planned using a 3D-printed model. Follow-up was conducted weekly for the first month and monthly for the next two months, with semiannual visits thereafter.

RESULTS:

Of the 50 patients, 42 % were male, and 58 % were female, with a mean age of 43 ± 8.75 years. Most patients (88 %) were diabetic. Maxillectomy defects were categorized as type IIA, IIB, IIIA, IIIB, and IV based on the Cordeiro classification. Four flaps (8 %) required re-exploration, with three salvaged. Complications included marginal flap necrosis (4 %) and oro-nasal fistula (2 %). The average hospital stay was six days, extended to ten days for re-explored cases. Flap dimensions varied with the largest being 62 cm² for the free fibula flap.

CONCLUSIONS:

Delayed reconstruction using free flaps in patients with post-COVID-19 mucormycosis maxillectomy defects without skin involvement is a safe approach with minimal morbidity. This method allows confirmation of disease resolution before major reconstructive surgery, resulting in excellent aesthetic and functional outcomes.

243

项与两性霉素B 相关的新闻（医药）

2025-02-18

·美通社

欣必松®（两性霉素B脂质体）首张处方落地

上海 2025年2月18日 /美通社/ -- 2025年2月18日，欣必松 ® （注射用两性霉素B脂质体）在西安交通大学第一附属医院开出全国首张处方，正式迈入临床应用新阶段，为广大侵袭性真菌病患者带来治疗新选择。靶向克菌重塑抗真菌治疗新标杆近年来，随着广谱抗生素、抗肿瘤药物、免疫抑制剂等的广泛应用，以及造血干细胞移植、器官移植等技术的开展，侵袭性真菌病的发病率及死亡率呈明显上升趋势。研究显示 [ 1 ] ，全球每年有超过 655 万人受到真菌疾病的影响，导致超过 375 万人死亡，其中约 255 万人的死亡可直接归因于真菌疾病，给临床带来巨大挑战。现阶段，抗真菌药物中三唑类、棘白菌素类，抗菌谱相对窄且容易出现耐药；另外，普通两性霉素B（AmB-D），肾毒性高且容易出现输注反应，都未能充分满足临床需求。面对当前耐药真菌、少见/罕见真菌的感染挑战，亟需新型抗真菌治疗方案，帮助患者渡过难关。其中，两性霉素B脂质体（L-AmB）凭借革命性脂质体包裹技术，精准输送药物至感染组织部位，游离药物释放减少，突破性实现高效杀菌与安全性双提升。研究显示 [ 2 ] [ 3 ] ：L-AmB因脂质体体积小，较少被肾脏过滤，避免AmB与远端小管细胞的相互作用，明显改善肾毒性；同时因能降低促炎细胞因子的上调，进而减弱输液反应。作为一款高效低毒的抗真菌利器，可为临床医生提供更优选择。突破壁垒为患者提供更多选择注射用两性霉素B脂质体，已在全球范围内广泛使用近30年，被誉为侵袭性真菌病治疗的"金标准" [ 3 ][ 4 ] 。由于其技术壁垒高，面临着活性成分水溶解性差、制备过程中易产生杂质、工艺多且复杂，周期长等众多难题，研发挑战巨大。济民可信集团创新技术药物研究院利用脂质体技术平台，突破关键技术，通过药学、非临床和临床试验研究证明了欣必松 ® （两性霉素B脂质体）与参比制剂药学和生物等效，并于2025年1月8日获得国家药品监督管理局核准签发的《药品注册证书》。欣必松 ® 按新4类注册要求，以高标准研制，视同通过一致性评价，有望进一步降低临床负担，为中国侵袭性真菌病患者带来更多获益。参考文献 1. Denning DW. Lancet Infect Dis. 2024 Jul;24(7):e428-e438. 2. Adler-Moore J, et al. Clin Infect Dis. 2019，68(S4):S244-S259. 3. Aversa F, et al. J Chemother. 2017 Jun;29(3):131-143. 4. 中华内科杂志,2024,63(3):230-257.

一致性评价临床研究

2025-02-06

·CPHI制药在线

黑热病治疗新靶点展望

关注并星标CPHI制药在线利什曼病，又被称为黑热病，是人体被利什曼原虫感染所致的播散性原虫病。有20个种类的利什曼原虫可引起利什曼病，大约30种不同的白蛉亚科沙蝇可以通过叮咬传播利什曼原虫，利什曼原虫感染已经成为许多热带和亚热带国家人群重要的卫生健康问题，是仅次于疟疾的最危险的且被忽视的热带病，每年可造成50,000例死亡和330万伤残。利什曼病疫苗接种是一种有吸引力且可行的替代方法，但迄今还没有疫苗或药物能完全根除或提供对利什曼病长期有效的免疫力。它有多种临床表现形式，如内脏利什曼病、皮肤利什曼病、粘膜利什曼病。世界卫生组织估计，该疾病每年影响 103 万人。目前临床治疗黑热病可供选择的药物种类少，治疗方法包括抗睾丸素、两性霉素 B 和米替福新，都受到了副作用、成本、耐药性和减毒等因素的制约。探索新的治疗靶点，如关键的代谢酶和表面活性蛋白，可能会开发出更有效和无毒的药物。治疗新靶点展望 1. 钙离子稳态调节剂钙是寄生虫生存所必需的，因此是治疗黑热病的一个靶点。钙离子在利什曼病菌的入侵和新陈代谢中起着至关重要的作用，钙离子浓度可以影响细胞内的信号通路。钙离子浓度的变化会触发寄生虫分化和细胞改变的信号通路。钙离子在调节寄生虫生命周期中的重要作用凸显了靶向钙转运体的潜在治疗作用。最近的研究表明，姜黄素等制剂能通过破坏钙离子转运体，诱导利什曼原虫的程序性细胞死亡。以前报道的钙通道阻滞剂，如芬地林、米贝地尔和利多法嗪等钙通道阻滞剂与常规化疗药物联合使用，具有很强的抗黑热病作用。 2. 铁离子稳态调节剂铁是参与新陈代谢的重要金属离子，通常以亚铁和铁两种状态存在。持续的氧化还原循环使生物体能够进行生存所需的各种重要生物过程。利什曼缺乏铁储存系统，是血红素辅助营养体，因此，铁清除对其生存和毒性至关重要。在缺铁条件下，会表达一种名为利什曼病菌铁转运体的铁转运体，通过提高铁的转运能力来获得所需的铁。铁是线粒体超氧化物歧化酶的关键成分，对氧化还原反应起关键作用，这种化合物可被视为药物开发的潜在目标。 3. 基因组靶点利什曼原虫的基因组结构与其他真核生物相比是独特的，没有内含子，并且由染色体中高度浓缩的基因密度组成在较小的核空间内。这些基因组负责编码各种蛋白质，这些蛋白质参与细胞的功能。其中一组蛋白质是利什曼原虫激酶，参与信号级联的调控，因此有可能成为有希望的分子靶标。最近研究人员开始研究蛋白激酶，如细胞周期蛋白依赖性激酶、糖原合酶激酶 3、双特异性酪氨酸调节激酶和丝裂原活化蛋白激酶等。 4. 蛋白酶体靶点蛋白酶体是一种复杂的蛋白质结构，负责调节蛋白质合成并分解折叠错误的蛋白质，而在原核生物中，被降解的蛋白质会被泛素标记。已经筛选了几种蛋白酶体抑制剂，其中一种是 GSK3494245/ DDD01305143/化合物，并在 2024 年完成了 I 期人体临床试验（https:// clinicaltrials.gov/study/NCT04504435）。此外，GNF6702 是一种细胞蛋白酶抑制剂化合物，诺华公司于 2020 年对其进行了化学优化，目前正在进行第二阶段人体临床试验。 5. 植物提取物从枸橼酸香蒲叶子中提取的精油，从柠檬香蒲叶中提取的精油在体外具有抗利什曼病的作用。此外，芦荟叶提取物通过诱导程序性细胞死亡发挥潜在抗利什曼病特性。 6. 宿主抗原疗法目前利什曼原虫感染的药物治疗效有限，需要长期用药，而且可能会导致严重的全身副作用，其严重程度超过了治疗效果。因此，要成功治疗由细胞内病原体引起的疾病，可能需要使用综合疗法和高效的给药方法。目前，咪喹莫特和雷喹莫特被用于治疗利什曼病AR-12 是塞来昔布的一种衍生物，可以增强宿主细胞对凋亡的抵抗力，可能破坏寄生虫诱导的 Akt 信号激活。辛伐他汀、洛伐他汀被用作局部或全身的宿主导向药物疗法，可抑制胆固醇的生成，促进巨噬细胞中吞噬体的成熟，从而提高寄生虫的清除率。 7. 纳米药物寄生虫的复杂生命周期和细胞内定位导致生物利用率较低，疗效降低。生物传感器和纳米载体辅助治疗和免疫，可彻底改变利什曼病的诊断、管理和预防。以纳米粒子为基础的递送系统通过改善靶向递送和抗原，纳米颗粒给药系统通过改善靶向给药和抗原呈递，刺激免疫系统，促进强大的 T 细胞反应，并在传染病防治中提供保障。脂质体纳米颗粒是一种水性支架，有助于亲水性和亲油性药物的附着，在体内的持久性更强，可在血液中停留较长时间，脂质体能以较低的剂量和给药频率持续、规范地释放药物。不同的纳米材料，如固体脂质纳米粒子、纳米悬浮剂、聚合物基纳米粒子、聚乙烯醇等不同的纳米材料，可以作为治疗利什曼病的各种药物的载体材料。参考文献 1. Singh VK, Tiwari R, Rajneesh, et al. Advancing Treatment for Leishmaniasis: From Overcoming Challenges to Embracing Therapeutic Innovations. ACS Infect Dis. 2024 Dec 31. 2. Kumar, R.; Chauhan, S. B.; Ng, S. S.; et al. Immune checkpoint targets for host-directed therapy to prevent and treat leishmaniasis. Front Immunol. 2017, 8, 1492. 3. Jamshaid, H.; Din, F. U.; Khan, G. M. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight. J. Nanobiotechnology. 2021, 19, 1?51. 扫码领取CPHI & PMEC China 2025展会门票【智药研习社近期直播】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

疫苗

2025-02-01

·GlobeNewswire-Health Care

Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea

January 28, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales in 2024 of the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole) exceeded thresholds triggering sales milestone payments from distribution partners to Basilea, in the total amount of approximately CHF 2.2 million. For Cresemba, this comprises a milestone payment for sales in Canada, by AVIR Pharma Inc, as well as the first sales milestone payment for the Middle East and North Africa (MENA) region, by Hikma Pharmaceuticals LLC. For Zevtera, this reflects a milestone payment in Europe, by Advanz Pharma. David Veitch, Chief Executive Officer, said: “We are very pleased with the commercial progress of our two commercialized brands in Canada, the MENA region and Europe. Their continued growth confirms that Cresemba and Zevtera are serving significant medical needs around the world.” Basilea’s commercial partnerships cover well over 100 countries worldwide. By year-end 2024, Cresemba was marketed in more than 70 countries while Zevtera was marketed in 20 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2023 and September 2024 amounted to USD 533 million, a 20 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1 Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba®. In Canada, Cresemba is approved for use in adults and pediatrics from 1 year up to 18 years for the treatment of invasive aspergillosis and invasive mucormycosis.2 In countries of the MENA region, it is indicated in adults for the treatment of invasive aspergillosis and for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate. Isavuconazole is also approved in the United States (US),3 the EU4 and several additional countries in Europe and beyond, including Japan and China.5 Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria.6 In several countries in Europe, the brand is approved as Zevtera® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP).6 Zevtera is also approved in the United States7, 8, China and several other countries.5 Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. References IQVIA Analytics Link, September 2024. In-market sales reported as moving annual total (MAT) in US dollar. Health Canada, Cresemba® (isavuconazole) Product Monograph: https://pdf.hres.ca/dpd_pm/00077745.PDF [Accessed: January 27, 2025] Full US prescribing information: https://www.astellas.us/docs/cresemba.pdf [Accessed: January 27, 2025] European Public Assessment Report (EPAR): https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed: January 27, 2025] The registration status and approved indications may vary from country to country. Summary of Product Characteristics (SmPC) Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: January 27, 2025] The content above comes from the network. if any infringement, please contact us to modify.

上市批准

100 项与两性霉素B 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00203	两性霉素B	G01AA03 J02AA01 A01AB04	DB00681

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
利什曼病	日本	Sumitomo Pharma Co., Ltd.	2009-06-17
粒细胞减少性发热	日本	Sumitomo Pharma Co., Ltd.	2006-04-20
念珠菌病	日本	Fuji Pharma Co., Ltd.	1997-01-31
侵袭性真菌感染	日本	Clinigen KK	1963-04-18
真菌病	-	Bristol Myers Squibb Co.	1958-01-01
复杂的尿路感染	中国	-	-
细菌性心内膜炎	中国	-	-
脑膜炎	中国	-	-
脓毒症	中国	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
隐球菌脑膜炎	临床3期	-	Matinas Biopharma Nanotechnologies, Inc.	2023-01-01
肺部疾病	临床3期	美国	Enzon Pharmaceuticals, Inc.	2005-10-01
侵袭性念珠菌病	临床2期	-	石药集团中奇制药技术（天津）有限公司	2020-01-01
侵袭性曲霉菌病	临床2期	-	石药集团中奇制药技术（天津）有限公司	2020-01-01
急性髓性白血病	临床2期	-	Matinas Biopharma Nanotechnologies, Inc.	2019-08-01
前体B细胞急性淋巴细胞白血病	临床2期	-	Matinas Biopharma Nanotechnologies, Inc.	2019-08-01
外阴阴道念珠菌病	临床2期	美国	Matinas Biopharma Nanotechnologies, Inc.	2016-11-01
酵母菌感染	临床2期	美国	Matinas Biopharma Nanotechnologies, Inc.	2016-11-01
慢性皮肤黏膜念珠菌病	临床2期	美国	Matinas Biopharma Nanotechnologies, Inc.	2016-09-27
口腔念珠菌病	临床2期	美国	Bristol Myers Squibb Co.	2001-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2024	N/A	-	-	Amphotericin B	廠壓夢鏇積鏇網憲鏇構(選觸網衊艱齋製顧繭夢) = 糧鬱選製遞範艱獵繭鑰淵遞齋淵艱廠餘衊遞齋 (醖醖觸壓鹹觸繭遞觸構 )	-	2024-06-09
EHA2024	N/A	血液肿瘤	21	Liposomal Amphotericin B (L-AMB) (Group A (poor response to other antifungal drugs))	網構遞壓窪簾範糧鏇遞(簾鹹積範鹽齋鹹積簾膚) = 鑰淵選積糧醖範遞獵鹽壓膚廠餘餘艱遞築簾餘 (醖膚壓廠觸鹽範獵繭簾 )	积极	2024-05-14
EHA2024	N/A	血液肿瘤	21	Liposomal Amphotericin B (L-AMB) (Group B (cannot tolerate adverse reactions))	網構遞壓窪簾範糧鏇遞(簾鹹積範鹽齋鹹積簾膚) = 獵構製襯鹽夢製壓膚觸壓膚廠餘餘艱遞築簾餘 (醖膚壓廠觸鹽範獵繭簾 )	积极	2024-05-14
GlobeNewswire 人工标引	N/A	镰刀菌病	3	MAT2203	觸築觸衊憲醖獵鬱鏇簾(顧壓鹽廠膚獵衊蓋觸夢) = 窪憲廠鏇鏇顧願鑰製簾繭餘願鏇積製繭鹽積鏇 (鹽醖願選獵簾齋壓積積 )	积极	2024-03-22
GlobeNewswire 人工标引	N/A	侵袭性真菌感染	19	MAT2203	壓襯鏇齋獵築鬱膚積廠(鬱艱鑰鬱願糧艱蓋憲築) = 製憲窪窪艱膚糧鑰夢製衊鹹憲築淵顧淵醖壓積 (蓋襯醖艱齋選膚構鹽廠 ) 更多	积极	2024-02-26
APAO2024	N/A	-	-	Optisol-GS with amphotericin B supplementation	積築淵繭壓醖餘構衊襯(鹹鏇廠簾窪壓鬱襯選壓) = 艱憲鏇鑰醖鬱鏇糧遞鏇憲範積構遞夢夢選範鏇 (鑰廠醖顧齋鑰壓淵夢獵 ) 更多	-	2024-02-22
APAO2024	N/A	-	-	Optisol-GS without amphotericin B supplementation	積築淵繭壓醖餘構衊襯(鹹鏇廠簾窪壓鬱襯選壓) = 顧窪膚齋襯憲壓糧遞膚憲範積構遞夢夢選範鏇 (鑰廠醖顧齋鑰壓淵夢獵 ) 更多	-	2024-02-22
NCT05814432 (not available, Pubmed \| Clin Infect Dis)	临床2期	组织胞浆菌病 \| HIV感染 CD4+	118	Single dose 10 mg/kg of L-AmB	蓋鑰夢遞衊願鬱蓋選衊(夢襯衊鹹壓範繭積遞積) = 蓋鑰觸糧築窪鏇醖網壓夢鬱窪簾餘範繭夢餘淵 (糧衊選簾遞鹽顧鏇淵鹽 ) 更多	积极	2023-10-13
NCT05814432 (not available, Pubmed \| Clin Infect Dis)	临床2期	组织胞浆菌病 \| HIV感染 CD4+	118	10 mg/kg of L-AmB on D1, and 5 mg/kg of L-AmB on D3	蓋鑰夢遞衊願鬱蓋選衊(夢襯衊鹹壓範繭積遞積) = 夢衊鏇窪網獵網鏇鏇襯夢鬱窪簾餘範繭夢餘淵 (糧衊選簾遞鹽顧鏇淵鹽 ) 更多	积极	2023-10-13
WCD2023	N/A	皮肤利什曼病	28	Liposomal amphotericin B 12 mg/kg	餘簾醖窪製窪齋糧範遞(鏇夢齋觸衊鑰醖窪顧網) = 廠窪窪艱築獵製艱糧窪簾壓鏇蓋願鹽網範餘簾 (製艱獵觸襯願築構蓋鹽 ) 更多	积极	2023-07-06
WCD2023	N/A	皮肤利什曼病	28	Liposomal amphotericin B 18 mg/kg	餘簾醖窪製窪齋糧範遞(鏇夢齋觸衊鑰醖窪顧網) = 餘鹽壓選選壓範願積製簾壓鏇蓋願鹽網範餘簾 (製艱獵觸襯願築構蓋鹽 ) 更多	积极	2023-07-06
ISN WCN2023	N/A	毛霉菌病	-	Liposomal amphotericin (LAmB)	壓夢窪鏇憲壓製糧醖蓋(選構夢壓鹹範繭遞膚繭) = 觸廠選積襯衊餘壓餘獵淵鬱網範襯製獵選繭鬱 (積網網遞壓衊憲襯醖範 ) 更多	-	2023-03-01
APAO2023	N/A	新型冠状病毒感染 \| 毛霉菌病	-	Transcutaneous Retrobulbar Amphotericin B	構壓夢衊遞遞製膚淵鬱(醖簾鏇齋鑰衊簾齋網顧) = 襯鹹鏇壓鬱範顧觸糧觸糧壓鑰築壓艱餘簾艱廠 (築繭膚範築觸鹽壓願夢 )	积极	2023-02-23
ASN2022	临床2期	艾滋病相关机会致病菌感染 cystatin C \| fractional excretion of sodium \| fractional excretions of potassium	90	Liposomal Amphotericin B 3 mg/kg for 14 days	蓋鏇鹹齋鑰艱艱築觸簾(構醖積獵憲壓網願範糧) = 襯鹹獵遞蓋憲憲鹽鬱膚窪夢觸淵獵繭醖鹽蓋鏇 (糧簾壓網鹽簾遞製鑰簾 ) 更多	积极	2022-11-03